Marion Johnson
Allergy · Los Angeles, CANPI 1952523086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 145 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$823
- Regeneron Healthcare Solutions, Inc.$468
- GSK$398
- AstraZeneca$347
- Biocryst US Sales Co., LLC$266
- Takeda Pharmaceuticals U.S.A., Inc.$261
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,079100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 23 | $823 |
| Regeneron Healthcare Solutions, Inc. | 19 | $468 |
| GSK | 10 | $398 |
| AstraZeneca | 12 | $347 |
| Biocryst US Sales Co., LLC | 11 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $261 |
| Pharming Healthcare, Inc. | 6 | $179 |
| Novartis | 6 | $155 |
| Pfizer | 6 | $125 |
| Kaleo, Inc. | 5 | $124 |
| Grifols USA, LLC | 4 | $114 |
| CSL Behring | 4 | $110 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $106 |
| Amgen | 5 | $97 |
| Covis Pharma GmbH | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Cycle Pharmaceuticals Inc | 2 | $63 |
| Genentech USA, Inc. | 3 | $62 |
| Ionis Pharmaceuticals, Inc. | 2 | $60 |
| Biocryst Pharmaceuticals, Inc. | 1 | $56 |
| Octapharma USA, Inc. | 2 | $50 |
| Optinose US, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,079 in reported general payments places this provider in the 60th percentile of 117 allergy providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Epinephrine | 13 | $1,652 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $615 |
| Azelastine Hcl | 28 | $571 |
| Ipratropium Bromide | 15 | $542 |
| Levocetirizine Dihydrochloride | 27 | $145 |
Paid to pharmacies, not to this prescriber.
Other allergy in Los Angeles
- Jonathan TamLos Angeles$33K
- Ricardo TanLos Angeles$18K
- Maxine BaumLos Angeles$10K
- Robert EitchesLos Angeles$7K
- Michael KaplanLos Angeles$2K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.